Overview

PD-L1 Expression Detection with the SP263 clone uses immunohistochemistry to visualize the PD-L1 protein on formalin-fixed, paraffin-embedded tumor sections. The SP263 antibody is a rabbit monoclonal reagent developed for the VENTANA automated staining platform, and it serves as a companion diagnostic that helps determine eligibility for several immune checkpoint inhibitors. Understanding the assay's principle clarifies why results are reported as a proportion of stained cells rather than a simple positive or negative call.

The Staining Principle

The method begins by applying the anti-PD-L1 antibody to a thin tissue slide, where it binds the PD-L1 protein expressed on the cell membrane. A secondary detection system then deposits a chromogen that renders bound sites as a visible brown stain under the microscope. Because PD-L1 sits on the cell surface, scoring focuses on membranous staining, and the intensity is interpreted against validated thresholds rather than estimated by eye alone.

Reading the Tumor Proportion Score

Pathologists evaluate the percentage of viable tumor cells showing partial or complete membrane staining, an approach known as the tumor proportion score. Different companion diagnostic claims use different cut-offs: for example, atezolizumab in non-small cell lung cancer is linked to a threshold of at least one percent tumor cell staining, while cemiplimab in certain indications uses a higher tumor cell threshold. The same SP263 assay can therefore support multiple immunotherapy decisions depending on the validated scoring rule applied.

Why Clone Choice Matters

PD-L1 assays are not interchangeable, because each antibody clone recognizes a slightly different epitope and each platform has its own staining chemistry. Laboratories should report the exact clone and scoring algorithm used so the clinician can match the result to the correct drug label. A clearly documented, standardized workflow protects the clinical meaning of the score across sites.

Pre-Analytical Factors That Affect the Score

Sample quality strongly influences the PD-L1 score. Fixation that is too long or too short can alter membrane antigen retention, and poor tumor content leaves too few cells to score reliably. Laboratories should define acceptable fixation times and minimum tumor area before staining, and flag specimens that fall outside those limits. A result reported with its pre-analytical context is far more trustworthy than a number issued without caveats.

FAQ

Q: What does SP263 actually measure? A: It measures PD-L1 protein on cell membranes in a tissue section by chromogenic immunohistochemistry, expressed as a proportion of stained tumor cells.

Q: Are all PD-L1 tests interchangeable? A: No, different antibody clones and platforms are validated separately, so the reported clone and scoring rule must match the intended therapy.

Q: Why is the result a percentage rather than a yes or no? A: Companion diagnostic claims are tied to proportion thresholds, so the score must reflect how many tumor cells express the marker.